Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

In a population not selected for risk, the cumulative incidence of atopic dermatitis at 24 months was 36.1% for those in the daily emollients group versus 43% for those in the control group (relative ...

Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the lightning round, Cramer replied that he is holding out hope for the ...

As usual, the one-two punch of ASCO and BIO set us a bit behind, but never fear – your June hires round-up is here at least ...

Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key d ...